France-based Rythm has raised $4 million from prominent entrepreneurs Dr. Laurent Alexandre, an influential biotech investor and telecommunication mogul, Xavier Niel, as well as public grants, bringing its total funding to date to $11 million.

The company has developed Dreem, a headband designed to increase sleep quality. Using advanced sensor technology typically found in sleep labs and hospitals, Dreem can track and analyze brainwaves in real-time and at distinct moments in a sleep cycle, provide sound stimulations to enhance the deep sleep. In addition, the device also ensures that its users wake up feeling refreshed via a smart alarm feature.

Dreem can track and analyze brainwaves in real-time and provide sound stimulations to enhance the deep sleep.The funds will enable the company to build a team of 50 employees, specialized in neuroscience, engineering and mathematics.

“Beyond Dreem, we’re working with leading academic experts and our talented team of engineers and scientists to develop a multitude of possibilities for further products to solve everyday human problems, in areas like sleep quality, learning, entertainment, and various others that we haven’t even dreamed of yet,” Rythm’s CEO and co-founder Hugo Mercier said in a statement. “For us, this is just the beginning.”

In addition to funding, Rythm announced they’re conducting clinical trials with the French Armed Forces Biomedical Research Institute (IRBA) and academic research team (EA 7330, Hôtel-Dieu, Paris Descartes University) in order to assess the Dreem headband on people with unconventional sleep routines. These trials aim to showcase how Dreem improves sleep on both “normal” nights and during periods of sleep loss.

Through Rythm’s Dreem First program, Dreem is available now for $349 at Rythm.co and is supported via mobile apps on iOS devices.